News

The Phase III trial results demonstrated that patients administered with pasireotide long-acting release (LAR) achieved greater disease control when compared to continued treatment with the standard somatostatin analogue

The Phase Ib/IIa study will evaluate the safety, tolerability and pharmacokinetics of a single ascending dose of COVA322, a bispecific TNF/IL-17A inhibitor. The randomized, double-blind, placebo-controlled will enroll

Novogen and Genea Biocells have already conducted preliminary research and found that super-benzopyrans appear to be effective at promoting the ‘normalization’ of stem cells associated with some forms

Currently, OncoMed is conducting a Phase Ib clinical trial of demcizumab in combination with Abraxane (nab-paclitaxel) and gemcitabine in first-line Stage IV pancreatic cancer patients. OncoMed chairman and

ORALAIR is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro

CRF trustee and president Nancy Stack noted that the foundation is on the brink of new possibilities and treatments. Stack spoke of CRF-funded stem cell and gene therapy

The study is aimed at evaluating numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes to better understand the

Study site for this first enrollment is Malaysia. The Phase III study has been designed to evaluate the safety, efficacy and pharmacokinetics of its rVIII-SingleChain for the treatment

Ruthigen plans to begin its combined Phase I/II clinical trial for its lead drug candidate RUT58-60 as early as July 2014. The study may be conducted at up